What are GH secretagogue peptides?
GH secretagogue peptides are synthetic compounds that engage growth hormone-releasing hormone receptors (GHRH-R) or ghrelin receptors (GHS-R1a) on pituitary somatotrophs, triggering growth hormone release downstream. The class splits into two mechanistically distinct groups: GHRH analogs — CJC-1295, Sermorelin, and Tesamorelin — that activate GHRH-R through Gs-protein coupling and cAMP elevation; and ghrelin receptor agonists like Ipamorelin that signal through phospholipase C and intracellular calcium mobilization. Both receptor types have been characterized as GPCRs in published pituitary cell culture and animal model studies (PMID: 15775957). The downstream pathways differ: GHRH receptor activation feeds cAMP-dependent growth hormone synthesis and secretion, while ghrelin receptor activation operates through a calcium-dependent route. These are research tools for studying endocrine signaling and pituitary receptor pharmacology, not therapeutic agents.
How do CJC-1295 variants differ?
The CJC-1295 family splits at pharmacokinetics. Both variants are 29-amino acid GHRH analogs with the same sequence substitutions at positions 2, 8, 15, 16, 23, 24, and 28 — those substitutions are what improve metabolic stability relative to native GHRH (PMID: 15775957). The difference is what happens after injection in the research model. CJC-1295 without DAC (also called Modified GRF 1-29) circulates and clears relatively quickly. CJC-1295 with DAC adds an albumin-binding Drug Affinity Complex moiety that creates a circulating depot, releasing active peptide gradually over an extended window (PMID: 16452336). The DAC version extends terminal half-life substantially; the tradeoff is slower onset at the receptor. Both activate GHRH-R through the same mechanism — cAMP elevation and downstream growth hormone secretion — but their time profiles in research models differ enough to matter for experimental design. Short-duration activation studies often use the no-DAC form; sustained GHRH-R exposure protocols favor the DAC variant. Both require HPLC purity and mass spectrometry identity confirmation before use.
What is the molecular structure of Ipamorelin?
Ipamorelin is the odd one out in this comparison — a 5-residue synthetic peptide where the others are 29-44 residues. Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2, with aminoisobutyric acid (Aib) at position 1 and D-2-naphthylalanine at position 3. Molecular formula C₃₈H₄₉N₉O₅; molecular weight 711.9 g/mol (PMID: 10698741). The D-amino acids at the D-2-Nal and D-Phe positions introduce proteolytic resistance — a structural solution to the degradation problem that differs from the albumin-binding approach used in CJC-1295 DAC. C-terminal amidation adds further stability. Published binding studies document that Ipamorelin activates GHS-R1a with high affinity and minimal cross-reactivity at other pituitary hormone receptors — ACTH, prolactin, and cortisol pathways are not significantly engaged (PMID: 11916262). That selectivity is one of the things that distinguishes Ipamorelin from earlier, non-selective GHRP compounds in the research literature. It works through a different receptor and a different intracellular signaling cascade than the GHRH analogs, which is why the two classes can be studied in combination with appropriate controls.
How does Sermorelin differ from native GHRH?
Sermorelin is the simplest compound in this group: a 29-residue synthetic peptide that replicates the GHRH(1-29) sequence exactly, with acetic acid modification. Full sequence: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2; molecular weight 3357.9 g/mol for the acetate salt (PMID: 8421207). Native GHRH runs to 44 amino acids; published structure-activity work shows the C-terminal residues from 30 to 44 contribute to metabolic stability but not to receptor binding or activation. Sermorelin retains the full binding-active sequence without those stability extensions — and without the sequence modifications found in CJC-1295. The consequence is a compound that activates GHRH receptors through the native Gs-cAMP mechanism but with faster clearance than modified analogs. For research protocols where native GHRH-like pharmacokinetics matter, or where a clean sequence comparison is needed between native and modified forms, Sermorelin is the appropriate reference compound.
What modifications does Tesamorelin contain?
Tesamorelin preserves the full 44-amino acid native GHRH sequence and modifies it at one location: a trans-3-hexenoyl group attached to tyrosine at position 1. Molecular weight 5135.9 g/mol (PMID: 19928588). The hexenoyl addition increases lipophilicity, which reduces renal clearance and lowers susceptibility to proteolytic degradation without touching the receptor-binding sequence. That is a different engineering approach than CJC-1295, which substitutes amino acids within the sequence to achieve stability gains. Tesamorelin gets its extended half-life from reduced clearance kinetics; CJC-1295 gets it from both reduced clearance and modified sequence stability. Published binding studies confirm Tesamorelin activates GHRH-R through Gs-protein coupling with potency comparable to native GHRH — the hexenoyl modification improves pharmacokinetics without altering receptor pharmacology. Research applications use Tesamorelin when sustained GHRH receptor activation over an extended observation window is the experimental requirement.
Side-by-Side Comparison Table
| Feature | CJC-1295 NO DAC (Mod GRF 1-29) | CJC-1295 DAC | Ipamorelin | Sermorelin | Tesamorelin |
|---|---|---|---|---|---|
| Amino Acids | 29 | 29 | 5 | 29 | 44 |
| Molecular Weight | 3367.9 Da | 3647.4 Da | 711.9 Da | 3357.9 Da | 5135.9 Da |
| CAS Number | Mod GRF 1-29 | 863288-34-0 | 170851-70-4 | 86168-78-7 | 218949-48-5 |
| Receptor | GHRH-R | GHRH-R | GHS-R1a | GHRH-R | GHRH-R |
| Selectivity | GHRH selective | GHRH selective | GH selective | GHRH selective | GHRH selective |
| Key Modification | Sequence substitutions | DAC albumin binding | D-amino acids | Native sequence | Hexenoyl group |
| Mechanism | cAMP/PKA | cAMP/PKA | PLC/Ca2+ | cAMP/PKA | cAMP/PKA |
| Primary PMID | 15775957 | 16452336 | 10698741 | 8421207 | 19928588 |
FAQ
What concentration is used for GHRH receptor research?
Published in vitro studies typically run 1-100 nM concentrations for GHRH receptor activation in pituitary cell cultures. Higher concentrations (100-1000 nM) may be used for receptor internalization or binding studies. Verify receptor expression in your cell model before committing to a concentration range.
Do GH secretagogues require GHRH for activity?
Ipamorelin and other GHS-R1a agonists stimulate GH release independently of GHRH — they act through a distinct receptor and signaling cascade. Published research documents this in the absence of exogenous GHRH, though synergistic effects appear when both classes are combined.
What cell lines express GHRH receptors?
Published protocols use primary pituitary cells, AtT-20 pituitary tumor cells, and HEK293 cells transfected with recombinant GHRH-R. Verify receptor expression through binding assays or qPCR before experimental use (PMID: 15775957).
How stable are these peptides in culture media?
Stability depends on the compound's structural modifications. Published protocols typically use freshly prepared solutions and include protease inhibitors in media. CJC-1295 analogs with sequence substitutions show better stability than native GHRH sequences under equivalent conditions (PMID: 16452336).
Can these peptides be used in combination?
Published research documents synergistic GH release when GHRH analogs and ghrelin receptor agonists are combined — the distinct receptor mechanisms make combination experiments tractable. Design with appropriate controls to isolate individual compound contributions from synergistic effects.
Research Use Only: All compounds sold by Cowboy Chems are intended exclusively for laboratory research. Not for human or animal consumption. These products are not drugs, supplements, or food. Statements have not been evaluated by the FDA. Must be 21+ to purchase.